Description: Why Abbott’s Price Target Just Nudged Higher Abbott Laboratories has seen its implied fair value estimate edge to about US$144.75 from about US$144.43, a very small upward move that still matters for investors tracking the story closely. The shift sits alongside a slightly lower 7.81% discount rate and essentially unchanged long term revenue growth assumptions of about 7.64%. Together, these factors echo the Street’s mixed but generally constructive read on Abbott’s execution, medical devices...

Description: Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: Dexcom achieved FY25 revenues of around $4.66bn, corresponding to a 16% uplift over FY24.

Description: The infant formula market presents opportunities in premiumization, digital transformation, and supply chain enhancement. Companies can leverage consumer demand for organic and plant-based options, utilize digital channels for personalized engagement, and strengthen partnerships for supply resilience and competitive positioning. Infant Formula Milk & Powder Market Infant Formula Milk & Powder Market Dublin, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The "Infant Formula Milk & Powder Market - Global Forec

Description: Innovative Health, Inc. today announced that the company has received its 50th clearance from FDA to reprocess single-use medical devices used in electrophysiology and cardiology labs. This latest clearance is to reprocess the Agilis NxT Steerable Introducer, originally manufactured by Abbott, for two additional uses in the lab. Innovative Health is the only reprocessing company that is cleared to reprocess this market-leading introducer two (2) times.

Description: Key Insights Institutions' substantial holdings in Abbott Laboratories implies that they have significant influence...

Description: The latest trading day saw Abbott (ABT) settling at $124.64, representing a -1.02% change from its previous close.

Description: Abbott Laboratories (ABT) has drawn fresh attention after unveiling Libre Assist, an AI driven feature in its Libre app that offers real time meal guidance for U.S. diabetes patients using continuous glucose data. See our latest analysis for Abbott Laboratories. The Libre Assist launch comes as Abbott’s 1 month share price return sits at 4.07% and its year to date share price return is 1.60%, while the 1 year total shareholder return of 12.53% points to steady momentum rather than a sharp re...

Description: Dividend aristocrats get plenty of attention, but most of the time the spotlight falls on the big names like Johnson & Johnson (NYSE:JNJ), Coca-Cola (NYSE:KO), and Procter & Gamble (NYSE:PG), among others. These are the names and stocks that dominate articles around dividend growth and, unsurprisingly, fill up income portfolios around the country. There is ... The Dividend Aristocrats No One’s Talking About (And Their 30+ Year Track Records)

Description: PBH vs. ABT: Which Stock Is the Better Value Option?

Description: Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in every province across Canadavi, in federal plans like Non-Insured Health Benefits (NIHB)vi and by a majority of employer-sponsored workplace benefits programs.i Coverage means more Canadians living with diabetes can experience the ease of the world's smallest glucose sensor.iv,v

Description: The two properties strengthen the Company's presence in Illinois, where it currently owns and manages three other properties. LAS VEGAS, NEVADA / ACCESS Newswire / January 7, 2026 / Sentinel Net Lease (the "Company") announced today that Sentinel ...

Description: PBH vs. ABT: Which Stock Is the Better Value Option?

Description: In early January 2026, Abbott Laboratories unveiled Libre Assist, an AI-powered feature within its Libre app that helps U.S. diabetes patients predict the glucose impact of meals in real time by analyzing food photos or descriptions and integrating data from its FreeStyle Libre continuous glucose monitoring sensors. By combining generative AI with continuous glucose data to give pre-meal guidance and post-meal feedback, Libre Assist highlights Abbott’s push to turn its Libre ecosystem into a...

Description: In the latest trading session, Abbott (ABT) closed at $126.45, marking a +1.82% move from the previous day.

Description: Abbott (NYSE: ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, before the market opens.

Description: Abbott (NYSE: ABT), a leading healthcare company, today unveiled Libre Assist,1 a groundbreaking feature within the Libre app5 designed to help the millions of people living with diabetes in the U.S. better understand how the foods they eat affect their glucose levels. 1,2 Unlike traditional food logging apps that only give feedback after a meal is logged, Libre Assist1 helps people make informed mealtime decisions before they eat. Abbott is launching the new technology during CES 2026 in Las Ve

Description: HOLX nears its 52-week high on diagnostics growth and AI adoption, while tariffs and challenges in China continue to pose risks.

Description: They can help you weather the storm.

Description: For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Description: Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: Abbott Laboratories (NYSE:ABT) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 22, Abbott Laboratories (NYSE:ABT) said the US Food and Drug Administration has approved the company’s Volt™ PFA System to treat patients with atrial fibrillation, or AFib. The company plans to begin commercial PFA cases in the United […]

Description: Key states, including California and Texas, lead in demand due to advanced healthcare systems and aging populations U.S. Embolic Protection Device Market U.S. Embolic Protection Device Market Dublin, Dec. 29, 2025 (GLOBE NEWSWIRE) -- The "United States Embolic Protection Device Market Report by Product, Application, Material, End-User, States and Company Analysis, 2025-2033" has been added to ResearchAndMarkets.com's offering.United States Embolic Protection Device Market is expected to reach US

Description: It is hard to get excited after looking at Abbott Laboratories' (NYSE:ABT) recent performance, when its stock has...

Description: HOLX's GYN Surgical unit gains momentum as the demand for gynecological devices rises globally, driven by innovation, M&A and strong overseas adoption.

Description: Abbott Laboratories is expected to release its fiscal fourth-quarter earnings soon, and analysts project a low double-digit profit growth.

Description: BSX's Endoscopy unit targets an $8B market, spanning pancreaticobiliary, surgery and obesity, with plans to outgrow the market.

Description: ABT wins FDA approval for its Volt PFA System for AFib, paving the way for U.S. launches and EU expansion after earlier CE Mark clearance.

Description: If you have been wondering whether Abbott Laboratories is still a buy at around $125 a share, you are not alone. This is exactly the kind of stock where valuation really matters. Despite slipping about 2.5% over the last week and 2.3% over the past month, Abbott is still up 10.4% year to date and roughly 11.6% over the last year, which keeps it firmly on investors radar as a steady compounder. Recent attention on Abbott has centered on its medical devices and diagnostics businesses,...

Description: Abbott’s latest regulatory progress supports its durable growth narrative. Is now the right time to revisit ABT shares?

Description: Boston Scientific trades at a premium, but strong momentum in WATCHMAN, EP and MedSurg growth keeps long-term shareholders in the game despite valuation risks.

Description: New heart device targets atrial fibrillation

Description: Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Volt™ PFA System to treat patients battling atrial fibrillation (AFib). Abbott will soon begin commercial PFA cases in the United States and will continue its expansion of sites in the European Union following Volt CE Mark approval earlier this year.

Description: The main point of investing for the long term is to make money. But more than that, you probably want to see it rise...

Description: Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.

Description: Wonderinterest Trading, a regulated investment firm operating across global markets, assessed sustainability-focused investing by analyzing the leading companies as presented in the Dow Jones Sustainability World Index (DJSI World).

Description: Abbott Laboratories (ABT) just picked up fresh FDA clearance and a CE Mark for its Amplatzer Piccolo Delivery System, a pediatric heart device upgrade that could quietly strengthen both its structural heart franchise and its long term growth story. See our latest analysis for Abbott Laboratories. These approvals land while Abbott’s 1 year total shareholder return of 15.35 percent and double digit year to date share price return signal steady, if not explosive, momentum, supported by board...

Description: Abbott Laboratories recently received U.S. FDA clearance and CE Mark for its Amplatzer Piccolo Delivery System, enabling more precise, minimally invasive closure of patent ductus arteriosus in premature infants using Abbott’s pea‑sized Amplatzer Piccolo Occluder. This advancement deepens Abbott’s presence in pediatric cardiology by expanding its portfolio of specialized devices for critically ill newborns, potentially strengthening hospital adoption of its broader structural heart...

Description: Parnassus Investments, an investment management firm, released its “Parnassus Value Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund focuses on owning a concentrated portfolio of U.S. large-cap stocks. For the third quarter of 2025, the fund reported a net return of 7.46% outperforming its benchmark, the […]

Description: Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its Amplatzer Piccolo™ Delivery System, which is used with the company's Amplatzer Piccolo Occluder. The new delivery system is designed specifically to treat premature babies (some weighing as little as two pounds) with a hole in the heart known as a patent ductus arteriosus (PDA).

Description: The healthcare sector is a great place to find quality income stocks, and these two appear to be strong picks.

Description: PBH vs. ABT: Which Stock Is the Better Value Option?

Description: Exact Sciences stock now sits at the center of a tightening deal spread, with our fair value estimate holding steady near $103.67 per share. This closely tracks the proposed $105 takeout price even as the discount rate edges up to 7.27 and long term revenue growth expectations tick higher to 12.44. These subtle shifts in the model reflect how the market is increasingly viewing the story through the lens of deal completion, while still acknowledging improving topline momentum in the core...

Description: Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...

Description: The global blood glucose monitor market is set to expand from USD 16.5 billion in 2025 to USD 25.4 billion by 2030, growing at a CAGR of 9.1%. This growth is fueled by the increasing prevalence of diabetes, a rising geriatric population, and enhanced self-monitoring awareness. Technological advancements in continuous glucose monitoring (CGM), smartphone integration, and AI data analytics have boosted accuracy and patient engagement. The self-monitoring blood glucose systems segment leads in mark

Description: Earlier this week, Needham downgraded Haemonetics from “Buy” to “Hold,” pointing to intensifying competition in vascular closure devices from Abbott and Cordis and warning that this could weigh on the company’s Interventional Technologies segment through fiscal year 2027. At the same time, Riverwater Partners exited its Haemonetics position, reallocating capital to companies with clearer near-term catalysts even as it acknowledged Haemonetics’ essential role in hospital blood management and...

Description: The latest trading day saw Abbott (ABT) settling at $128.47, representing a +2.4% change from its previous close.

Description: Shares of blood products company Haemonetics (NYSE:HAE). fell 4.3% in the afternoon session after Needham downgraded the stock from 'Buy' to 'Hold', citing concerns about growing competition.

Description: ABT expands its Lingo biowearable to Android, broadening access to real-time glucose tracking and pushing continuous monitoring into mainstream wellness.

Description: Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Description: Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 63 cents per share, an increase of 6.8%. The company's quarterly dividend payout has increased more than 70% since 2020.

Description: HOLX's Diagnostics gains accelerate as U.S. molecular testing drives growth and new Panther Fusion and Genius platform approvals widen its runway.

Description: The autoimmune disease diagnosis market is poised to grow from USD 5.57 billion in 2025 to USD 8.98 billion by 2031, exhibiting a CAGR of 8.3%. Key growth drivers include rising autoimmune disorder prevalence, increased awareness of early detection, and technological advances. Systemic autoimmune diseases lead in market share due to conditions like rheumatoid arthritis and lupus necessitating complex diagnostics. The Asia Pacific region is the fastest-growing, driven by healthcare advancements.

Description: In early December 2025, Medtronic’s board approved a US$0.71 per-share cash dividend for the third quarter of fiscal 2026, payable on January 16, 2026, and the company secured FDA clearance for its Hugo robotic-assisted surgery system in urologic procedures while launching its MiniMed 780G system with Abbott’s Instinct sensor across the U.S. Together, these developments highlight how Medtronic is pairing a long-running dividend growth record with fresh momentum in robotics and diabetes...

Description: The baby-formula giant is pressuring Washington with a high-stakes ultimatum as lawsuits mount and regulators watch.

Description: BSX builds momentum in PFA as FARAPULSE posts strong growth, and new trial results and expanded FDA labeling boost its AF treatment push.

Description: Several non-biotech healthcare stocks are starting to show real momentum, breaking out of bases and asserting themselves as leaders in the sector. With improving volume patterns, accelerating relative strength, and clean technical setups, this group of medical technology, services, and equipment stocks is quickly becoming one of the strongest pockets in the market. As buyers rotate toward areas showing sustained upside follow-through, these healthcare names look poised to extend their momentum and deliver standout performance in the weeks ahead.

Description: Key Insights Significantly high institutional ownership implies Abbott Laboratories' stock price is sensitive to their...

Description: The DNA Diagnostics Market is set to surge from USD 13.07 billion in 2024 to USD 21.69 billion by 2030, growing at a CAGR of 8.81%. Key trends driving this growth include the emergence of liquid biopsies, the rise of direct-to-consumer testing, the shift to smart bioinformatics, and advancements in genomics and personalized medicine. Increasing genetic disorder prevalence, improved DNA sequencing technology, and expanded diagnostic applications further fuel market expansion. North America leads

Description: In the latest trading session, Abbott (ABT) closed at $122.09, marking a -2.39% move from the previous day.

Description: Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally different healthcare bets. Abbott delivered steady 6.9% revenue growth anchored by medical devices. Lilly posted explosive 54% revenue growth powered by its GLP-1 obesity and diabetes drugs. Medical Devices Carry Abbott. GLP-1s Carry Lilly. Abbott’s medical device segment ... Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump

Description: Hologic shares rise 16% in six months, with divisional strength clinical data and a go-private deal shaping the short-term outlook.

Description: Abbott (NYSE: ABT) today announced that Lingo, an over-the-counter continuous glucose monitor (CGM) and app, is now available for Android devices. Already available for Apple iOS devices, this expansion gives millions more people access to real-time glucose data, empowering informed choices that help support better energy, sleep, focus and overall well-being.i ii iii

Description: Amid the nation's worst blood shortage in a generation, the University of Wisconsin rallied Big Ten students, fans and alumni to take action, winning the Abbott and the Big Ten Conference "We Give Blood" competition and inspiring 15,476 blood donations that could save up to 46,428 lives. Overall donations in the competition surged 319% compared to 2024, marking a dramatic expansion of efforts to confront the national blood shortages. In just the first 22 days of the initiative, donations surpass

Description: If you have been wondering whether Exact Sciences is still worth buying after its huge run, you are not alone. This breakdown is designed to help you decide if the current price makes sense. The stock has climbed to around $101.06, logging a powerful 45.1% gain over the last month and a 77.5% jump year to date, even though the last 5 years still show a -22.0% total return. Investors have been reacting to a steady stream of developments around Exact Sciences, including ongoing adoption of its...

Description: Wondering if Abbott Laboratories at around $125 a share is still a smart buy or if the best days are already priced in? You are not alone, and this breakdown is designed to give you a clear, valuation first answer. The stock is roughly flat over the last month at down 0.3%, but it is still up 10.5% year to date and over the past year, hinting that the market sees steady, not explosive, upside for now. Recent headlines have focused on Abbott's continued expansion of its medical devices and...

Description: HSBC, Abbott, Shell and Oak Valley feature in the latest Zacks Analyst Blog as analysts highlight operational resilience, strategic pivots and industry-specific challenges.

Description: HSBC's Asia pivot, Abbott's device momentum and Shell's resilient Q3 results headline today's standout analyst reports.

Description: With America's growing focus on wellness and the quality of your years, muscle is emerging as a new metric for aging. That's why Abbott (NYSE: ABT), a global leader in science-based nutrition, today announced two new shakes designed to support muscle health and nutrition goals as part of the Ensure Max Protein line: Ensure Max Protein 42g and Ensure Max Protein 2 in 1 Muscle Support.

Description: Don't bet against it.

Description: Manila, Dec. 04, 2025 (GLOBE NEWSWIRE) -- etaily, the Philippines’ digital-native retail platform, has secured new strategic investments led by Japan’s Sumitomo Mitsui Banking Corporation (SMBC), through its SMBC Asia Rising fund, bringing its total funding to over $24 million. Other investors in this round include Kaya Founders, JGDEV of the Gokongwei Group as well as other notable Asia-based families. etaily enables some of the world’s best-known consumer brands in Southeast Asia, including Le

Description: Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Description: Medtronic begins the U.S. rollout of MiniMed 780G with Abbott's Instinct sensor, advancing diabetes care.

Description: Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced the broad U.S. commercial launch of the MiniMed™ 780G system integrated with the Instinct sensor, made by Abbott and designed exclusively for MiniMed™ systems. Following U.S. FDA clearance of the system earlier this year to enable integration with the Instinct sensor, the system is now shipping to customers across the U.S., marking a major milestone in diabetes technology and delivering a smart, seamless way to mana

Description: For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Description: PBH vs. ABT: Which Stock Is the Better Value Option?

Description: The healthcare leader wants to make waves in a potentially highly lucrative market.

Description: Abbott Laboratories (NYSE:ABT) ranks among the best slow growth stocks to invest in. UBS reaffirmed its Buy rating and $158 price target for Abbott Laboratories (NYSE:ABT) on November 21 in response to the company’s agreed acquisition of Exact Sciences. In the largest acquisition in the medtech sector thus far this year, Abbott Laboratories (NYSE:ABT) signed […]

Description: Abbott Laboratories’ stock narrative is shifting as analysts adjust their consensus price target, which has edged down slightly from $144.47 to $144.43. This recent update comes alongside a range of views shaped by the company’s varied business performance and strategic moves. Stay tuned to see how you can monitor these market perspectives and keep up with evolving updates on Abbott’s outlook. Stay updated as the Fair Value for Abbott Laboratories shifts by adding it to your watchlist or...

Description: GE HealthCare (GEHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: The North American Nucleic Acid Amplification Testing (NAAT) market will reach $7.64 billion by 2033, growing from $3.28 billion in 2024 with a CAGR of 9.87%. Driven by technological advances, rising diagnostic demand, and widespread applications, NAAT proves critical in identifying infectious diseases and genetic mutations. Notably, innovation, automation, and government support bolster the market's expansion. Despite regulatory hurdles and high costs, ongoing collaborations aim to enhance affo

Description: The North America Heart Pump Device market is projected to grow from USD 2.92 billion in 2024 to USD 8.1 billion by 2033, reflecting a CAGR of 12% between 2025-2033. Key drivers include technological advancements, increasing heart disease prevalence, and a rising geriatric population. Devices like LVADs and total artificial hearts are crucial in treating advanced heart failure. The U.S. leads with a well-funded healthcare system, while Canada's universal healthcare supports access. Challenges in

Description: The Pediatric Interventional Cardiology Market is poised for significant growth, projected to rise from USD 2.42 billion in 2024 to USD 4.34 billion by 2033, exhibiting a 6.68% CAGR. This expansion is driven by the increasing prevalence of congenital heart defects such as VSD, PDA, and ASD in children. The advent of advanced medical devices and the shift towards non-invasive treatments also contribute to market growth. The U.S. stands out as a key player due to rising infant cardiac abnormalitie

Description: The United States STD Diagnostics Market is set to grow from US$ 5.06 billion in 2024 to US$ 8.49 billion by 2033, achieving a CAGR of 5.91% from 2025 to 2033. Key growth drivers include rising STD prevalence, technological advancements, increased awareness, and supportive government initiatives. Rapid point-of-care tests and molecular diagnostics are gaining traction, while high costs and regulatory hurdles persist as challenges. Major markets like California, Texas, New York, and Florida lead

Description: Extending Medicare reimbursement for cardiac catheter ablation to settings outside the hospital is expected to boost procedure volumes and benefit Abbott, Boston Scientific, J&J and Medtronic.

Description: Abbott Laboratories has lagged behind the S&P 500 in recent months as well as over the past year, yet analysts remain strongly bullish on the stock’s prospects.

Description: Abbott Laboratories (ABT) stock has caught the attention of investors after recent trading momentum shifted slightly upward this week. This move comes on the back of moderate gains over the past month, encouraging some renewed interest in the healthcare giant. See our latest analysis for Abbott Laboratories. This week’s upward momentum follows what has been a solid stretch for Abbott Laboratories, underscoring renewed optimism after a year of moderate but positive performance. While the share...

Description: Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.

Description: Brinker upgraded, Coinbase downgraded: Wall Street's top analyst calls

Description: BSX posts stronger Q3 margins as growth in EP and WATCHMAN lifts product mix despite tariff pressure.

Description: The Autoimmune Disease Diagnostics industry is set for significant growth, projected to leap from US$ 5.70 billion in 2024 to US$ 10.63 billion by 2033, at a CAGR of 7.17%. Key growth drivers include a rising need for precise diagnostic tools and a focus on enhanced patient outcomes. Innovations in diagnostic technologies and strategic partnerships among industry leaders are paving the way for improvements. Leading companies like Abbott Laboratories, Bio-Rad, Roche Diagnostics, and Siemens Healt

Description: Booking, Carvana upgraded: Wall Street's top analyst calls

Description: With its stock down 2.6% over the past three months, it is easy to disregard Abbott Laboratories (NYSE:ABT). But if you...

Description: Abbott Laboratories (NYSE:ABT) is one of the stocks Jim Cramer recently offered insights on. Cramer highlighted the company’s acquisition of Exact Sciences and said that it complements Abbott’s diagnostic business, as he remarked: “This morning, Abbott Labs announced that it’s buying Exact Sciences, that’s the colorectal cancer screening company, for about $21 billion. It’s a […]

Description: We recently published 10 Stocks Jim Cramer Talked About. Abbott Laboratories (NYSE:ABT) is one of the stocks Jim Cramer discussed. This show marked more than a month after Cramer discussed pharmaceuticals and diagnostics devices firm Abbott Laboratories (NYSE:ABT). However, the delay doesn’t mean he’s changed his sentiment about the firm. Cramer often calls Abbott Laboratories […]

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

Description: These healthcare stocks have long-term and profitable growth runways.

Description: Find insight on Abbott, Ryman Healthcare, Novartis and more in the latest Market Talks covering the health care sector.

Description: Earlier this month, Exact reported a record $851 million in third-quarter revenue, which included $666 million from its screening business.

Description: With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed.

Description: The proposed deal, the biggest under CEO Robert Ford’s tenure, would allow Abbott to enter a large, new market for cancer testing.

Description: These companies have been raising their payouts for a combined 101 consecutive years.

Description: The transaction includes the absorption of Exact Sciences’ estimated net debt of $1.8bn.

Description: Shares of Exact Sciences Corp. jumped after Abbott Laboratories announced a deal to acquire the cancer screening test maker for about $21 billion.

Description: 0939 ET – Abbott’s commercial infrastructure makes it a good fit for Exact Sciences, TD Cowen analyst Joshua Jennings said in a report issued shortly before the deal was formerly announced earlier today. “Abbott controls the largest primary care-facing point-of-care diagnostics footprint globally,” Jennings says. Additionally, Abbott’s large salesforce for its continuous glucose monitor products could be leveraged to boost sales through the primary care provider channel.

Description: ↗️ Walmart (WMT): The biggest U.S. retailer and private-sector employer posted solid quarterly results and raised its outlook. Shares closed up nearly 6.5%. ↘️Nvidia (NVDA): The chip maker reported record sales and issued strong guidance, helping ease angst about an artificial-intelligence bubble.

Description: Nvidia turns lower as strong earnings fail to assuage concerns over an artificial-intelligence bubble.

Description: Exact Sciences stock rocketed for a second day Thursday, after Abbott Laboratories confirmed a $23 bil. buyout deal.

Description: Health care stocks declined late Thursday afternoon with the NYSE Health Care Index and the Health C

Description: The company received a buyout offer from Abbot Labs.

Description: Abbott Laboratories announced a $21 billion deal Thursday morning to acquire Exact Sciences, the maker of Cologuard — its largest acquisition in a decade. The deal will allow Abbott — which makes medical tests, baby formula and continuous glucose monitors, among other products — to enter the cancer testing space. Exact Sciences focuses on early cancer detection and personalized treatments, and ...

Description: Exact Sciences stock rallies as Abbott announces a $21 billion deal to acquire to the molecular diagnostics firm. Here’s why EXAS shares are unlikely to push any higher in 2026.

Description: A healthcare giant covets the cancer screening leader's technology.

Description: Exact Sciences markets Cologuard as a non-invasive, convenient test. The traditional method of testing for colorectal cancer is a colonoscopy.

Description: The healthcare conglomerate Abbott Laboratories said on Thursday it would buy Exact Sciences makers of the at-home colon cancer test Cologuard, for roughly $21 billion. The deal appears to be the biggest healthcare acquisition announced this the year, and would be Abbott’s largest since 2017. Abbott will pay $105 per share of Exact Sciences, a 50% premium over Exact Sciences’ closing price on Tuesday of $69.68.

Description: All three major US stock indexes were up in late-morning trading after Nvidia (NVDA) reported strong

Description: Deal boosts ABT's cancer-screening footprint and long-term growth

Description: Abbott Laboratories (ABT) agreed to acquire cancer screening and diagnostics tests provider Exact Sc

Description: If you have ever wondered whether Abbott Laboratories is trading for more or less than its true value, you are in the right place. The stock has returned 11.2% year to date and 10.9% over the past 12 months, despite recent minor pullbacks of 2.1% in the last week and 2.6% in the last month. Recent headlines have focused on Abbott's continuous innovation in medical devices and its steady expansion into global healthcare markets. Industry analysts have also highlighted the company's strategic...

Description: Abbott Laboratories agreed to acquire cancer diagnostics company Exact Sciences in a deal valued at about $21 billion, as Abbott looks to compete in the burgeoning market for multi-cancer early detection tests. Exact Sciences shareholders will receive $105 a share. The stock rose 17.9% to $101.60 in morning trading after closing at $86.18 Wednesday.

Description: US healthcare group Abbott Laboratories has bet on rapid cancer testing to boost growth, striking a $23bn deal to buy Exact Sciences in its biggest...

Description: Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including Abbott Laboratories' (ABT) move to buy Exact Sciences (EXAS) in a $21 billion deal, reports that Verizon Communications (VZ) will be cutting over 13,000 jobs in its restructuring, and Bath & Body Works (BBWI) shares sinking after the brand cut its full-year earnings forecast. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.

Description: Investing.com -- Exact Sciences (NASDAQ:EXAS) stock soared 17% Thursday, building on Wednesday’s 24% surge after Abbott (NYSE:ABT) announced plans to acquire the cancer diagnostics company in a deal valued at approximately $21 billion.

Description: A strategic investor is reportedly in advanced talks to purchase the company.

Description: Exact Sciences stock catapulted Wednesday on a report that Abbott Laboratories is nearing a deal to buy the cancer-finding specialist.

Description: Shares of the cancer diagnostics company Exact Sciences surged 25% late Wednesday, after a report said the conglomerate Abbott Laboratories is close to a deal to acquire the company. Neither Abbott nor Exact Sciences immediately responded to a request for comment. The Bloomberg report didn’t include any financial terms of a potential deal.

Description: Investing.com -- Shares of Exact Sciences are soaring over 21% on Wednesday following a Bloomberg report that Abbott Laboratories is in advanced talks to acquire the medical-testing company.

Description: Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Description: Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Description: Boston Scientific rides on strong neuromodulation momentum as sales climb, new technologies gain traction and recent acquisitions expand its pain-treatment reach.

Description: HOLX's solid Q4 growth and a pending $18.3B buyout sharpen its focus as the company prepares to end its publicly traded chapter.

Description: Buying a low-cost index fund will get you the average market return. But across the board there are plenty of stocks...

Description: These stocks pay income that investors can count on over the long run.

Description: Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: BSX's month-long rally, strong Q3 beats and expansion into chronic pain solutions sharpen investor focus.

Description: There are a few key trends to look for if we want to identify the next multi-bagger. Ideally, a business will show two...

Description: Here are five Goldman Sachs stock picks that conservative growth and income investors should consider moving to for what could be a volatile 2026.

Description: Insulet is Thursday's IBD Stock Of The Day. After a wild post-earnings reaction, Insulet stock is in a consolidation with an early entry.

Description: Founder and Chief Executive Officer Will Ahmed said the business is well-positioned for an IPO now that it’s broadened its portfolio to include proprietary technology, hardware, software, analytics and other items, such as accessories and apparel. While Ahmed has previously said Whoop is likely to go public, he hadn’t shared when that might happen. “We like to build things ourselves and we really want to build this home of health for our members,” he added.

Description: The United States Dietary Supplements Market, projected to grow from US$ 54.24 billion in 2024 to US$ 103.56 billion by 2033, is driven by rising health awareness and demand for preventive healthcare, alongside growing fitness trends and an aging population. Busy lifestyles, online retail expansion, and innovation in supplement formulations further stimulate market growth. Popular for their role in enhancing immunity, fitness, and general health, dietary supplements include vitamins, minerals, a

Description: Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 Index continued its rally in the third quarter, ending the year-to-date returns at 13.7%. During this period, growth and momentum were key contributors to the […]

Description: J&J's MedTech sales rose 5.6% in Q3, fueled by cardiovascular strength and strategic portfolio shifts toward high-growth markets.

Description: This story has been updated to reflect the FDA's November 11, 2025, announcement. The baby formula market is dominated by a handful of companies, including Abbott Labs, Mead Johnson, and Nestle. Together, these companies account for more than 80% of the infant formula market in the U.S., according ...

Description: Abbott Laboratories (NYSE:ABT) is included among the 15 Best Dividend Growth Stocks to Buy Now. On October 24, Citi a‌nalyst Joanne Wuensch reaffirmed a Buy rating on​ Abbott Laboratories (NYSE:ABT), as reported by The Fly. She highlighted​ t‌h‍at Judg⁠e Pallmeyer of‌ the US Distr‌ict Court f‍or the Nort‍hern District of Illinois granted summary judgme⁠nt in […]

Description: Abbott Laboratories (ABT) just released its quarterly results, revealing revenue grew nearly 7% over last year, though it missed Wall Street estimates. The company kept its full-year outlook intact and narrowed adjusted EPS guidance. See our latest analysis for Abbott Laboratories. Abbott Laboratories’ 1-day share price return of 1.13% suggests investors remain upbeat after its latest report, even with revenue coming in below expectations. While momentum has softened recently, with a 30-day...

Description: In the past week, Abbott Laboratories reported its third quarter 2025 results, showing revenue up 6.9% year over year but missing Wall Street expectations and reaffirming its full-year outlook, while also completing the repurchase of more than 2.4 million shares for US$293.06 million under its ongoing buyback programs. Despite the revenue shortfall, the company’s ability to maintain its outlook and continue returning capital to shareholders through significant buybacks contributed to a...

Description: PONTE VEDRA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today reported its financial results for the third quarter ended September 30, 2025, and provided an update on the clinical development of tecarfarin and the acquisition and development of frunexian. Highlights Progressed clinical development of tecarfarin. Completed the manufacturi

Description: These companies have already handsomely rewarded longtime shareholders, and it's not too late to join the party.

Description: It’s been a great year for stocks, but in the past few days the bull market seems to have lost some of its mojo.

Description: "Driven by Technological Advances and Expanding Clinical Applications, Patient Monitoring Devices Are Revolutionizing Healthcare Delivery Across Hospitals, Home Care, and Remote Settings"Boston, Nov. 07, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Patient Monitoring Devices: Global Markets” is projected to grow from $36.7 billion in 2025 to $55.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.7% during the forecast period of 2025 to 2030.

Description: Despite underperforming the broader market over the past year, Wall Street analysts remain highly bullish on Abbott Laboratories' long-term outlook.

Description: Wondering if Abbott Laboratories is undervalued, fairly priced, or perhaps even a hidden bargain? You are not alone, as many investors are taking a closer look at this healthcare giant. The stock is up 9.8% year-to-date, despite a recent 6.9% dip in the last month. This highlights how sentiment and risk perception can change quickly. Investors have been reacting to headline-grabbing developments such as innovations in Abbott's medical device segment and new product...

Description: BSX's Q3 EP sales soar 63% on FARAPULSE momentum, FDA label expansion and rising global adoption.

Description: Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: Market trends indicate robust expansion in online retail, convenience stores, and prepared baby food segments. Leading countries like China and India bolster growth, with key players including Nestlé and Danone at the forefront. Asia-Pacific Organic Baby Food Market Asia-Pacific Organic Baby Food Market Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Organic Baby Food Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to ResearchAndMarkets.co

Description: This holiday season, global healthcare leader Abbott is adding even more heart to Hallmark Channel's beloved "Countdown to Christmas" lineup with a story that features a special community and is sure to spread joy and inspiration. "The More the Merrier," a new original Hallmark movie, features real-life heroes from Abbott HeartMates, a program that provides support for people impacted by heart health challenges. The movie is set to premiere during Hallmark's Merry Thanksgiving Weekend during "Co

Description: Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch1 of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial. Glenmark's 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) of Abbott Laboratories Pharmaceutical Products Division (Abbott) NDA - 019443. Glenmark will begin

Description: Key Insights Significantly high institutional ownership implies Abbott Laboratories' stock price is sensitive to their...

Description: The global disposable medical device market is set to expand from USD 113.95 billion in 2025 to USD 144.85 billion by 2030, driven by a 4.9% CAGR. Factors such as heightened concern over hospital-acquired infections (HAIs), increased surgical procedures, and demand for cost-effective, single-use solutions propel growth. The drug delivery devices segment is leading in growth due to rising chronic disease cases and vaccine programs. The plastic-based segment is growing due to cost-effectiveness an

Description: The HbA1c testing market presents opportunities driven by rising Type 2 diabetes cases and advancements in testing technologies. Supportive healthcare initiatives and increased awareness enhance demand. Strategic insights, competitive analysis, and diverse applications across settings highlight key investment areas. HbA1c Testing Market HbA1c Testing Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "HbA1c Testing Market Size, Share, Growth, Trends and Forecast 2025-2033" report has been adde

Description: Abbott Laboratories has seen its consensus analyst price target notch a slight increase, moving from $144.40 to $144.47, as updated research lends fresh nuance to the company's outlook. This modest adjustment reflects a blend of analyst optimism fueled by favorable legal developments and ongoing strength in its Medical Devices segment. However, there are also pockets of caution stemming from mixed quarterly results. Stay tuned to discover how investors and observers can stay ahead as the...

Description: Dexcom's solid third-quarter report was overshadowed Friday by its "surprisingly cautious" outlook, and Dexcom stock tumbled.

Description: Boston Teacher Shares Life-Changing Experience with Breakthrough Dual Chamber Leadless Pacemaker During Nationwide Interviews in Conjunction with D S Simon Media Boston Teacher Shares Life-Changing Experience with Breakthrough Dual Chamber Leadless Pacemaker During Nationwide Interviews in Conjunction with D S Simon Media. NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- A revolutionary advancement in cardiac care is changing what’s possible for people living with slow or abnormal heart rhythms. On O

Description: Hologic's $18.3B buyout deal and Abbott's strong growth across key segments set up a close contest for MedTech investors.

Description: The AI rally has many investors wondering where to turn in anticipation of its end. The medical-device maker is one solid option.

Description: Zacks analysts highlight IBM, Micron, and Abbott for their innovation-driven growth, solid fundamentals, and evolving market strategies.

Description: IBM posts strong Q3 results as Watsonx and quantum bets boost growth, while Micron rides AI-driven memory demand and Abbott expands on device strength.

Description: SAN DIEGO, October 29, 2025--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced that the t:slim X2 insulin pump, featuring Control-IQ+ automated insulin delivery (AID) technology, is now available with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor integration in the United States.* This is the first step in a global commercial rollout that expands choice and personalization for people living with diabetes w

Description: DXCM's Q3 results are likely to benefit from rising G7 use, early Stelo traction and expanding access across Type 2 diabetes markets.

Description: Key Insights The projected fair value for Abbott Laboratories is US$95.46 based on 2 Stage Free Cash Flow to Equity...

Description: The cardiovascular repair market is fueled by an aging population, technological advancements, and the rise in comorbidities. Opportunities lie in innovative, minimally invasive devices, value-based contracting, and regional market dynamics. Emphasizing personalized, data-driven solutions and supply chain resilience is crucial for growth. Cardiovascular Repair & Reconstruction Devices Market Cardiovascular Repair & Reconstruction Devices Market Dublin, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The "Card

Description: Founded in 1869, Goldman Sachs is the world’s second-largest investment bank by revenue and is ranked 55th on the Fortune 500 list of the largest United States corporations by total revenue. The Wall Street white-glove giant offers financing, advisory services, risk distribution, and hedging for the firm’s institutional and corporate clients. We review the firm’s ... Goldman Sachs Still Says Sell-Off Coming – 5 Safe Conviction List Picks

Description: Abbott Laboratories (ABT) stock has drifted slightly lower this month, with shares showing a 7% drop over the past month. However, year to date, the company has delivered an 11% gain, reflecting underlying strength in its business. See our latest analysis for Abbott Laboratories. After a steady climb earlier this year, Abbott Laboratories’ share price momentum has cooled off a bit, with the recent 1-month share price return of -7% standing out against an otherwise solid 11% year-to-date gain...

Description: The United States Chronic Obstructive Pulmonary Disease (COPD) Market is projected to grow from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, at a CAGR of 2.42%. Factors driving this growth include an aging population, heightened smoking rates, and environmental influences. The demand for innovative inhalers, biologics, and rehabilitation programs is rising. Key segments include chronic bronchitis and emphysema, with treatment options spanning drugs, oxygen therapy, and surgery. States l

Description: The GCC catheter market is projected to grow from USD 579.83 million in 2024 to USD 1.28 billion by 2033, with a CAGR of 9.21% from 2025 to 2033. This growth is driven by an increase in chronic diseases, surgical procedures, and advanced healthcare infrastructure across GCC countries. The demand for minimally invasive treatments and the aging population further bolster market expansion. Key sectors such as cardiovascular, microcatheters, and intermittent catheters are witnessing significant grow

Description: Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Description: Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: There's a shift towards plant-based sources like pea, soy, and quinoa, appealing to clean-label and allergen-free seekers. Innovations such as ready-to-drink beverages and gummies are expanding market appeal. North America leads, backed by strong fitness culture, while APAC shows the fastest growth. The market is highly fragmented with key players like Abbott, Glanbia, and Nestlé. E-commerce platforms are transforming distribution, offering convenience and variety. Global Protein Supplements Mar

Description: Abbott Laboratories’ third quarter results met Wall Street’s expectations for both revenue and non-GAAP profit, but the market reacted negatively, with shares declining over 4%. Management pointed to double-digit growth in medical devices, led by diabetes care and electrophysiology, as key drivers for the quarter. CEO Robert Ford commented that “recently launched new products generated nearly $5 billion in sales this quarter,” highlighting the contribution of new offerings. However, ongoing head

Description: The Global Functional Foods Market is set to expand at a CAGR of 7.92% from 2025 to 2033, reaching $678.32 billion by 2033, up from $341.6 billion in 2024. The surge is driven by increasing health awareness, demand for fortified foods, and an emphasis on preventive healthcare. Functional foods, enhanced with vitamins, minerals, and probiotics, are gaining traction among health-conscious consumers aiming to prevent chronic diseases. Key markets include the U.S., Germany, and India, with bakery an

Description: Abbott Laboratories (NYSE:ABT) ranks among the best medical device stocks to invest in. Benchmark began coverage of Abbott Laboratories (NYSE:ABT) on October 10 with a $145 price target and a Buy rating, describing the company as a reliable performer in a dynamic global environment. The firm claims that Abbott’s business strategy is unique in that […]

Description: The global home healthcare market is projected to reach USD 473.8 billion by 2030, up from USD 309.9 billion in 2025, growing at a CAGR of 8.9%. This expansion is driven by rising lifestyle-related disorders such as high blood pressure, obesity, and cardiac conditions. Leading companies are innovating and introducing new home healthcare products. The therapeutic products segment holds the largest market share, fueled by a growing prevalence of chronic health conditions. Skilled nursing services

Description: In October 2025, Abbott Laboratories reported third-quarter results showing US$11.37 billion in sales and reaffirmed its 2025 earnings guidance, narrowing expected full-year adjusted diluted EPS to US$5.12–US$5.18, while guiding for organic sales growth of 7.5%–8.0% excluding COVID-19 testing. Despite strong medical device sales, the company faced mixed results due to challenges in its diagnostics and nutrition segments, prompting investors to focus closely on its revised annual outlook and...

Description: Abbott, a global healthcare leader, and BIG CARiNG Group (BCG), one of Malaysia's largest retail pharmacies, announced a strategic three-year collaboration to promote influenza awareness across Malaysia. The Influenza Awareness Program, running from 2025 to 2027, is designed to elevate public understanding of influenza and encourage proactive health management.

Description: Key opportunities in the global patient monitoring devices market include expanding use of miniaturized multi-sensing devices and adoption due to stringent regulations, enhanced self-management of chronic diseases, and growth potential in emerging regions. Sustainability and ESG practices also offer competitive advantages. Patient Monitoring Devices Market Patient Monitoring Devices Market Dublin, Oct. 20, 2025 (GLOBE NEWSWIRE) -- The "Patient Monitoring Devices: Global Markets" report has been

Description: Abbott posts strong Q3 growth across key segments, but tariff pressures and weak Diagnostics weigh on near-term momentum.

Description: Here are the four new stock additions to the Goldman Sachs Conviction List for October—all outstanding total return ideas for growth and income investors.

Description: Third quarter earnings season is just beginning, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Abbott Laboratories' consensus analyst price target has seen a modest uptick, increasing from $142.48 to $144.40 following the company’s latest earnings update. This change reflects a blend of ongoing optimism about Abbott’s medical device growth and robust international presence, as well as some lingering concerns over near-term challenges. Stay tuned to discover how you can track these evolving perspectives and remain informed about Abbott’s shifting investment outlook. What Wall Street Has...